378 related articles for article (PubMed ID: 26507244)
1. The paracaspase MALT1: biological function and potential for therapeutic inhibition.
Jaworski M; Thome M
Cell Mol Life Sci; 2016 Feb; 73(3):459-73. PubMed ID: 26507244
[TBL] [Abstract][Full Text] [Related]
2. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.
Hailfinger S; Nogai H; Pelzer C; Jaworski M; Cabalzar K; Charton JE; Guzzardi M; Décaillet C; Grau M; Dörken B; Lenz P; Lenz G; Thome M
Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14596-601. PubMed ID: 21873235
[TBL] [Abstract][Full Text] [Related]
3. Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.
Juilland M; Thome M
Curr Opin Hematol; 2016 Jul; 23(4):402-9. PubMed ID: 27135977
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
[TBL] [Abstract][Full Text] [Related]
5. Regulation of NF-κB signaling by caspases and MALT1 paracaspase.
Staal J; Bekaert T; Beyaert R
Cell Res; 2011 Jan; 21(1):40-54. PubMed ID: 21119681
[TBL] [Abstract][Full Text] [Related]
6. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
8. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.
Jaworski M; Marsland BJ; Gehrig J; Held W; Favre S; Luther SA; Perroud M; Golshayan D; Gaide O; Thome M
EMBO J; 2014 Dec; 33(23):2765-81. PubMed ID: 25319413
[TBL] [Abstract][Full Text] [Related]
9. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
Mc Guire C; Elton L; Wieghofer P; Staal J; Voet S; Demeyer A; Nagel D; Krappmann D; Prinz M; Beyaert R; van Loo G
J Neuroinflammation; 2014 Jul; 11():124. PubMed ID: 25043939
[TBL] [Abstract][Full Text] [Related]
11. MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.
Baens M; Bonsignore L; Somers R; Vanderheydt C; Weeks SD; Gunnarsson J; Nilsson E; Roth RG; Thome M; Marynen P
PLoS One; 2014; 9(8):e103774. PubMed ID: 25105596
[TBL] [Abstract][Full Text] [Related]
12. Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.
Wu CH; Yang YH; Chen MR; Tsai CH; Cheng AL; Doong SL
PLoS One; 2018; 13(6):e0199779. PubMed ID: 29953499
[TBL] [Abstract][Full Text] [Related]
13. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
14. Differing Requirements for MALT1 Function in Peripheral B Cell Survival and Differentiation.
Lee P; Zhu Z; Hachmann J; Nojima T; Kitamura D; Salvesen G; Rickert RC
J Immunol; 2017 Feb; 198(3):1066-1080. PubMed ID: 28031341
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
16. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.
Gewies A; Gorka O; Bergmann H; Pechloff K; Petermann F; Jeltsch KM; Rudelius M; Kriegsmann M; Weichert W; Horsch M; Beckers J; Wurst W; Heikenwalder M; Korn T; Heissmeyer V; Ruland J
Cell Rep; 2014 Nov; 9(4):1292-305. PubMed ID: 25456129
[TBL] [Abstract][Full Text] [Related]
18. MALT1 protease: a new therapeutic target in B lymphoma and beyond?
McAllister-Lucas LM; Baens M; Lucas PC
Clin Cancer Res; 2011 Nov; 17(21):6623-31. PubMed ID: 21868762
[TBL] [Abstract][Full Text] [Related]
19. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
[TBL] [Abstract][Full Text] [Related]
20. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2.
Varfolomeev E; Wayson SM; Dixit VM; Fairbrother WJ; Vucic D
J Biol Chem; 2006 Sep; 281(39):29022-9. PubMed ID: 16891304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]